
A simulation-based technology for stochastic modeling, sensitivity analysis and design optimization, aimed at development of next-generation micro-fluidic devices for biomedical applications.Award last edited on: 8/4/2022
Sponsored Program
SBIRAwarding Agency
NIH : NIBIBTotal Award Amount
$232,115Award Phase
1Solicitation Topic Code
286Principal Investigator
Gaurav KewlaniCompany Information
Softworthy LLC
5900 Balcones Drive Suite 4215
Austin, TX 78731
Austin, TX 78731
(210) 425-3799 |
contact@softworthy.com |
www.softworthy.com |
Location: Single
Congr. District: 25
County: Travis
Congr. District: 25
County: Travis
Phase I
Contract Number: 1R43EB032276-01Start Date: 9/30/2021 Completed: 3/31/2022
Phase I year
2021Phase I Amount
$232,115Public Health Relevance Statement:
Infectious ailments affect more than 400M people worldwide annually, accounting for almost 30% of disability-adjusted-life-years (DALYs, i.e. number of years lost due to ill-health, disability or early death), and for many of these conditions, bringing affordable diagnosis & effective therapeutic drugs to the point-of-need is key to reducing morbidity and mortality. In this regard, micro-fluidics technology can be used to develop diagnostic tools for pathogen detection that offer quick turnaround, clinically relevant detection limit, & portability, and drug discovery platforms for therapeutic drug synthesis that offer rapid screening, high throughput, & reduced cost. The rising popularity of such technology and its growing demand is driving innovation toward devices that need to exhibit precision, durability, repeatability & reliability, and the proposed stochastic simulation-based technology would support the development of such robust solutions, resulting in safer, more effective biomedical devices that improve public health globally.
Project Terms:
Accounting ; Affect ; Air ; Algorithms ; Artificial Intelligence ; AI system ; Computer Reasoning ; Machine Intelligence ; Automobile Driving ; driving ; Biology ; Biomedical Engineering ; bio-engineered ; bio-engineers ; bioengineering ; Cells ; Cell Body ; Chemistry ; Comprehensive Health Care ; Comprehensive Healthcare ; comprehensive care ; Cessation of life ; Death ; Diagnosis ; Disease ; Disorder ; Disease Outbreaks ; Outbreaks ; Pharmaceutical Preparations ; Drugs ; Medication ; Pharmaceutic Preparations ; drug/agent ; Elements ; Engineering ; Epidemic ; Exhibits ; Genes ; Health ; Industry ; Infection ; Lead ; Pb element ; heavy metal Pb ; heavy metal lead ; Methods ; Methodology ; Polynomial Models ; polynomials ; Monte Carlo Method ; Monte Carlo algorithm ; Monte Carlo calculation ; Monte Carlo procedure ; Monte Carlo simulation ; Morbidity - disease rate ; Morbidity ; mortality ; Patients ; Physics ; Play ; Primary Health Care ; Primary Care ; Primary Healthcare ; Probability ; Productivity ; Public Health ; Quality Control ; research and development ; Development and Research ; R & D ; R&D ; Resources ; Research Resources ; Role ; social role ; Sensitivity and Specificity ; Computer software ; Software ; Software Design ; Designing computer software ; Technology ; Temperature ; Testing ; Thermal Conductivity ; Work ; Drug Delivery Systems ; Drug Delivery ; Device Designs ; Equipment Malfunction ; Device Failures ; Uncertainty ; doubt ; Guidelines ; base ; improved ; Specific qualifier value ; Specified ; Variant ; Variation ; Ensure ; Chemicals ; Evaluation ; Fiber ; disability ; insight ; Discipline ; Fostering ; Space Explorations ; Therapeutic ; tool ; Diagnostic ; Knowledge ; Adopted ; Investigation ; Complex ; Techniques ; System ; Healthcare Sector ; Health Care Sector ; Performance ; knowledgebase ; knowledge base ; Finite Element Analyses ; Finite Element Analysis ; simulation ; novel ; Environmental Factor ; environmental risk ; Environmental Risk Factor ; Devices ; Modeling ; response ; portability ; drug discovery ; Drug Synthesis and Chemistry ; drug synthesis ; µfluidic ; Microfluidics ; Address ; Microfluidic Device ; Microfluidic Lab-On-A-Chip ; microfluidic chip ; Microfluidic Microchips ; Food Safety ; global health ; Resolution ; Scheme ; Characteristics ; Process ; Development ; developmental ; Output ; disability-adjusted life years ; DALY ; cost ; digital ; software systems ; rapid detection ; design ; designing ; next generation ; Outcome ; prospective ; innovation ; innovate ; innovative ; Pathogen detection ; clinically relevant ; clinical relevance ; practical application ; application in practice ; multidisciplinary ; graphical user interface ; Graphical interface ; graphic user interface ; software user interface ; scientific computing ; reconstitution ; reconstitute ; engineering design ; commercial application ; prototype ; effective therapy ; effective treatment ; point-of-care diagnostics ; clinical decision-making ; simulation software ; screening ; Formulation ; microfluidic technology ; µfluidic technology ; recurrent neural network ; Rapid screening ; detection limit ; detection sensitivity ; therapeutically effective ;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00